CN102036671A - 使用脐带血细胞治疗脑损伤 - Google Patents

使用脐带血细胞治疗脑损伤 Download PDF

Info

Publication number
CN102036671A
CN102036671A CN2009801155168A CN200980115516A CN102036671A CN 102036671 A CN102036671 A CN 102036671A CN 2009801155168 A CN2009801155168 A CN 2009801155168A CN 200980115516 A CN200980115516 A CN 200980115516A CN 102036671 A CN102036671 A CN 102036671A
Authority
CN
China
Prior art keywords
cord blood
cells
blood cells
isolated population
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801155168A
Other languages
English (en)
Chinese (zh)
Inventor
S-Z·林
W-C·徐
H·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCyte Inc
Original Assignee
StemCyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by StemCyte Inc filed Critical StemCyte Inc
Publication of CN102036671A publication Critical patent/CN102036671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801155168A 2008-03-28 2009-03-26 使用脐带血细胞治疗脑损伤 Pending CN102036671A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7217308P 2008-03-28 2008-03-28
US61/072,173 2008-03-28
PCT/US2009/001915 WO2009120368A2 (en) 2008-03-28 2009-03-26 Treatment of brain damage using umbilical cord blood cells

Publications (1)

Publication Number Publication Date
CN102036671A true CN102036671A (zh) 2011-04-27

Family

ID=41114539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801155168A Pending CN102036671A (zh) 2008-03-28 2009-03-26 使用脐带血细胞治疗脑损伤

Country Status (10)

Country Link
US (1) US11318170B2 (enExample)
EP (1) EP2282748B1 (enExample)
JP (4) JP2011515470A (enExample)
CN (1) CN102036671A (enExample)
AU (1) AU2009229153B2 (enExample)
CA (1) CA2719740C (enExample)
IL (1) IL208406A0 (enExample)
SG (1) SG191701A1 (enExample)
TW (2) TW201636033A (enExample)
WO (1) WO2009120368A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
CN108269615A (zh) * 2018-03-14 2018-07-10 南宁市第人民医院 一种脐血pH值与婴幼儿脑损伤的关系评价方法
CN114466655A (zh) * 2019-08-20 2022-05-10 永生生技股份有限公司 心血管疾病的治疗

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
KR20140107439A (ko) * 2011-12-14 2014-09-04 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 중추신경계 손상 치료용 인간 단핵구의 서브집단 세포
WO2015174087A1 (ja) * 2014-05-16 2015-11-19 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5087570A (en) 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
AU2001243464B2 (en) 2000-03-09 2006-04-13 Saneron Ccel Therapeutics, Inc. Human cord blood as a source of neural tissue for repair of the brain and spinal cord
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
US8062837B2 (en) 2002-02-14 2011-11-22 Stemcyte, Inc. Plasma-depleted, not erythrocyte-depleted, cord blood compositions and method of making
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
DE10330216A1 (de) * 2003-07-03 2005-01-20 Jensen, Arne Wilhelm Oluf, Prof. Dr. Verwendung von Stammzellen aus Nabelschnurblut zur Verhinderung von Hirnschäden infolge Sauerstoffmangel und zur Neuroprotektion
BRPI0511287A (pt) * 2004-05-17 2007-12-04 Univ Minnesota uso de células-tronco do sangue do cordão umbilical para tratar evento isquêmico
US20060264365A1 (en) 2005-05-18 2006-11-23 Hung Li Treatment of brain tissue damage
US7569545B2 (en) 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
US7427597B2 (en) 2005-11-21 2008-09-23 Academia Sinica Method of treating brain tissue damages
US8329166B2 (en) 2005-12-16 2012-12-11 Academia Sinica Pluripotent olfactory stem cells
CA2762853A1 (en) 2009-05-21 2010-11-25 Stemcyte Inc. Cell therapy for brain tissue damage

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIELI CHEN等: "《Intravenous Administration of Human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats》", 《STROKE》 *
LU D等: "《Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury》", 《CELL TRANSPLANT》 *
郝思国等: "《人脐血CD133＋细胞体外短期培养中生物学特性的变化》", 《中国实验血液学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
CN108269615A (zh) * 2018-03-14 2018-07-10 南宁市第人民医院 一种脐血pH值与婴幼儿脑损伤的关系评价方法
CN114466655A (zh) * 2019-08-20 2022-05-10 永生生技股份有限公司 心血管疾病的治疗

Also Published As

Publication number Publication date
EP2282748A2 (en) 2011-02-16
AU2009229153B2 (en) 2015-06-11
EP2282748B1 (en) 2016-11-09
JP6655123B2 (ja) 2020-02-26
JP2018154634A (ja) 2018-10-04
JP6138090B2 (ja) 2017-05-31
JP2014237677A (ja) 2014-12-18
EP2282748A4 (en) 2012-01-11
CA2719740A1 (en) 2009-10-01
WO2009120368A2 (en) 2009-10-01
TW200948370A (en) 2009-12-01
AU2009229153A1 (en) 2009-10-01
TWI593417B (zh) 2017-08-01
JP2017031158A (ja) 2017-02-09
CA2719740C (en) 2018-11-20
JP6401757B2 (ja) 2018-10-10
TW201636033A (zh) 2016-10-16
US11318170B2 (en) 2022-05-03
IL208406A0 (en) 2010-12-30
US20110256107A1 (en) 2011-10-20
JP2011515470A (ja) 2011-05-19
WO2009120368A3 (en) 2010-01-07
SG191701A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
JP6655123B2 (ja) 臍帯血細胞を用いた脳損傷の処置
JP6519038B2 (ja) 脳梗塞治療のための多能性幹細胞
Lim et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia
Liao et al. Exogenous neural stem cell transplantation for cerebral ischemia
JP5649786B2 (ja) ヒト胚性幹細胞およびそれらの誘導体を含む組成物、使用方法、ならびに調製方法
WO2015088286A1 (ko) 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
US10383895B2 (en) Stimulation of therapeutic angiogenesis by T regulatory cells
JP7255805B2 (ja) 多能性幹細胞による胎児発育不全に伴う脳障害の改善及び治療
JP6604492B2 (ja) 脳梗塞治療のための多能性幹細胞
JP6994200B2 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
HK1153663B (en) Treatment of brain damage using umbilical cord blood cells
HK1153663A (en) Treatment of brain damage using umbilical cord blood cells
JPWO2018034314A1 (ja) 間葉系幹細胞活性化剤
US20240307452A1 (en) Umbilical cord blood mononuclear cells and red cell fraction improve neurogenesis and behavioral recovery after hypoxia-ischemic brain damage
US20200206077A1 (en) Autologous stem cell therapies for treatment of eye disease
Sharma et al. Role of stem cell therapy in treatment of muscular dystrophy
Zalewska Investigation of corticosterone impact on the sub-acute stage of recovery after photothrombotic stroke induction
England Mobilisation of endogenous haematopoietic stem cells and their use as treatment for subacute stroke
Vendrame Cord blood cell therapy for ischemic stroke

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110427